• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis

    Thumbnail
    View/Open
    Nash434736Published.pdf (503.0Kb)
    File version
    Version of Record (VoR)
    Author(s)
    Strand, Vibeke
    McInnes, Iain
    Mease, Philip
    Nash, Peter
    Thom, Howard
    Kalyvas, Chrysostomos
    Hunger, Matthias
    Gandhi, Kunal
    Pricop, Luminita
    Jugl, Steffen
    Choy, Ernest
    Griffith University Author(s)
    Nash, Peter
    Year published
    2019
    Metadata
    Show full item record
    Abstract
    Aim: To compare secukinumab with infliximab in biologic-naive patients with psoriatic arthritis using matching-adjusted indirect comparison. Patients & methods: Individual patient baseline data for secukinumab were matched to published aggregate data for infliximab by key baseline characteristics, with matching weights determined by logistic regression, and used to recalculate American College of Rheumatology (ACR) responses for secukinumab, for comparison with infliximab. Results: There were no differences in outcomes between secukinumab and infliximab at weeks 6/8 and 14/16. At weeks 24 and 54/52, ACR 20 responses were ...
    View more >
    Aim: To compare secukinumab with infliximab in biologic-naive patients with psoriatic arthritis using matching-adjusted indirect comparison. Patients & methods: Individual patient baseline data for secukinumab were matched to published aggregate data for infliximab by key baseline characteristics, with matching weights determined by logistic regression, and used to recalculate American College of Rheumatology (ACR) responses for secukinumab, for comparison with infliximab. Results: There were no differences in outcomes between secukinumab and infliximab at weeks 6/8 and 14/16. At weeks 24 and 54/52, ACR 20 responses were higher with secukinumab 150 mg than infliximab. At week 54/52, ACR 20/50 responses were higher for secukinumab 300 mg than infliximab. Conclusion: In the mid to long term, patients receiving secukinumab were more likely to achieve ACR 20/50 responses than those receiving infliximab.
    View less >
    Journal Title
    Journal of Comparative Effectiveness Research
    Volume
    8
    Issue
    7
    DOI
    https://doi.org/10.2217/cer-2018-0141
    Copyright Statement
    © 2019 The Authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License, which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
    Subject
    Rheumatology and arthritis
    Immunology
    Science & Technology
    Life Sciences & Biomedicine
    Health Care Sciences & Services
    comparative effectiveness
    infliximab
    Publication URI
    http://hdl.handle.net/10072/396670
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander